Kinnov Therapeutics

Kinnov Therapeutics

First-in-class therapy for a worldwide market

Menu

  • Company
  • Alcohol addiction
  • R&D / Pipeline
  • Product KT-110
  • Partners / Investors
  • Business strategy
  • News
  • Contact us

New investigators for phase 2 clinical trial

New investigators for phase 2 clinical trial

Prof. Henri-Jean Aubin, Hôpital Paul Brousse, Villejuif, accepts the function of Principal Investigator Dr. Ivan Berlin, Hôpital Pitié-Salpêtrière, Paris, accepts the function of Co-Investigator Prof. Henri-Jean Aubin and Dr. Ivan Berlin, are internationally renowned for their competence in alcohol and

kinnov February 8, 2016February 8, 2016 Uncategorized Read more

Welcome on our website

Welcome on our website

The new Kinnov Therapeutics website is launched. Welcome ! Feel free to contact us if you have any question.

kinnov December 21, 2015February 8, 2016 Uncategorized Read more

BPI France validates the Kinnov-Therapeutics project

BPI France validates the Kinnov-Therapeutics project

BPI FRANCE has validated the Kinnov-Therapeutics project in 2015 by supporting the phase 2 clinical trial.       The Région Centre also participates to this adventure.       More information about our goal.

kinnov December 8, 2015February 8, 2016 Uncategorized Read more

Co-funded by the horizon 2020 programme of the European Union

About us

Kinnov Therapeutics is dedicated to the R&D of innovative therapies against addiction. Supported by experienced scientists in the drug discovery and development, we have identified the key receptors of addiction. KT-110, our first-in-class lead composition, has been tested in phase 2 clinical trial for alcohol addiction.

Contact Us

Kinnov-Therapeutics

3, allée du titane
45100 Orléans, France


View Larger Map

Pages

  • Addictions: a major Public Health threat
  • Alcohol addiction
  • Business strategy
  • Company
  • Contact us
  • Home
  • Partners / Investors
  • Preclinical trials
  • Product KT-110
  • R&D / Pipeline

Copyright 2020 - Kinnov Therapeutics